Should And Would Amgen Break Itself Up?
In the wake of yesterday’s pharma-deal madness (Novartis NVS -2.76% swapping assets with GlaxoSmithKline GSK +0.34% and selling its animal health division to Eli Lilly; Valeant and Bill Ackman making a hostile bid for Botox-maker Allergan AGN -0.79%), Bernstein analyst Geoffrey Porges sent a note out to investors asking what it might all mean for biotech stocks.
Hey, check out all the research scientist jobs. Post your resume today!